Literature DB >> 9233633

Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein.

J M Calvo-Calle1, J Hammer, F Sinigaglia, P Clavijo, Z R Moya-Castro, E H Nardin.   

Abstract

The efficacy of a malaria peptide vaccine would be enhanced by the inclusion of a parasite-derived universal T cell epitope to ensure that all vaccinees develop parasite-specific cellular and humoral immunity. Two circumsporozoite (CS) protein T cell epitopes, previously identified by CD4+ T cell clones derived from Plasmodium falciparum sporozoite-immunized volunteers, were studied to determine their HLA class II binding potential. One epitope, located in amino acid (aa) 326-345 of the P. falciparum (NF54 strain) CS protein, was "universal" in that it could bind to multiple DR and DQ molecules in vitro. In contrast, the second epitope, T1, which is located in the CS repeat region, was recognized by T cells in the context of DQ6 (DQB1*0603) and did not bind with high affinity to any of the class II molecules tested in the peptide binding assays. The in vitro patterns of peptide/HLA interactions correlated with immunogenicity in vivo. A multiple antigen peptide (MAP) containing the aa 326-345 epitope elicited responses in eight inbred strains (H-2(a,b,d,k,p,q,r,s)), while the T1 MAP was recognized by only a single haplotype, H-2b. The combination of the universal aa 326-345 T cell epitope and the T1 repeat in a di-epitope MAP overcame the genetic restriction to the P. falciparum CS repeat region and elicited antisporozoite Ab responses in all of the MAP-immunized mice. Synthetic peptide malaria vaccines containing the aa 326-345 universal T cell epitope would be expected to elicit parasite-specific immune responses in both sporozoite-primed and naive individuals of diverse genetic backgrounds.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9233633

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Interaction of HLA and age on levels of antibody to Plasmodium falciparum rhoptry-associated proteins 1 and 2.

Authors:  A Johnson; R Leke; L Harun; C Ginsberg; J Ngogang; A Stowers; A Saul; I A Quakyi
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Novel promiscuous HLA-DQ HIV Nef peptide that induces IFN-gamma-producing memory CD4+ T cells.

Authors:  V Pancré; B Georges; G Angyalosi; F Castelli; A Delanoye; M Delacre; E Hachulla; B Maillere; A Bouzidi; C Auriault
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

3.  Intrahaplotype and interhaplotype pairing of bovine leukocyte antigen DQA and DQB molecules generate functional DQ molecules important for priming CD4(+) T-lymphocyte responses.

Authors:  Junzo Norimine; Wendy C Brown
Journal:  Immunogenetics       Date:  2005-11-08       Impact factor: 2.846

4.  A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII.

Authors:  Takayuki Shiratsuchi; Urvashi Rai; Izumi Kaneko; Min Zhang; Shiroh Iwanaga; Masao Yuda; Moriya Tsuji
Journal:  Vaccine       Date:  2017-10-28       Impact factor: 3.641

5.  Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms.

Authors:  Jean-Noel Billaud; Darrell Peterson; Byung O Lee; Toshiyuki Maruyama; Antony Chen; Matti Sallberg; Fermin Garduño; Phillip Goldstein; Janice Hughes; Joyce Jones; David Milich
Journal:  Vaccine       Date:  2006-11-17       Impact factor: 3.641

6.  The promise and challenge of epitope-focused vaccines.

Authors:  Jon Oscherwitz
Journal:  Hum Vaccin Immunother       Date:  2016-04-08       Impact factor: 3.452

7.  A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts.

Authors:  A Birkett; K Lyons; A Schmidt; D Boyd; G A Oliveira; A Siddique; R Nussenzweig; J M Calvo-Calle; E Nardin
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

8.  Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin.

Authors:  Daniel Carapau; Robert Mitchell; Adéla Nacer; Alan Shaw; Caroline Othoro; Ute Frevert; Elizabeth Nardin
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

9.  Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.

Authors:  Thomas J Powell; Jie Tang; Mary E Derome; Robert A Mitchell; Andrea Jacobs; Yanhong Deng; Naveen Palath; Edwin Cardenas; James G Boyd; Elizabeth Nardin
Journal:  Vaccine       Date:  2013-02-26       Impact factor: 3.641

10.  Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.

Authors:  Caroline Othoro; Dean Johnston; Rebecca Lee; Jonathan Soverow; Jean-Claude Bystryn; Elizabeth Nardin
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.